Seek Returns

JAZZ vs. VTRS: Jazz Pharmaceuticals vs. Viatris Stock Comparison

How do Jazz Pharmaceuticals (JAZZ) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Jazz Pharmaceuticals (JAZZ) and Viatris (VTRS) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Company profile comparison for Jazz Pharmaceuticals (JAZZ) and Viatris (VTRS)
Profile ItemJAZZVTRS
NameJazz Pharmaceuticals plcViatris Inc.
Country/RegionIrelandUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticalsPharmaceuticals
GICS Sub-IndustryPharmaceuticalsPharmaceuticals
Market Capitalization15.07 billion USD22.83 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJune 1, 2007March 17, 1980
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

JAZZ
VTRS
GSPC
Loading price history…
Jazz Pharmaceuticals (JAZZ) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Jazz Pharmaceuticals (JAZZ) and Viatris (VTRS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Jazz Pharmaceuticals (JAZZ) and Viatris (VTRS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Jazz Pharmaceuticals (JAZZ) and Viatris (VTRS)
MetricJAZZVTRS
Total Return (1Y)84.44%108.98%
Total Return (3Y, Annualized)27.57%36.75%
Total Return (5Y, Annualized)12.88%11.59%

Risk Profile

Drawdown History

JAZZ
VTRS
GSPC
Loading price history…
Jazz Pharmaceuticals (JAZZ) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Jazz Pharmaceuticals (JAZZ) and Viatris (VTRS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Jazz Pharmaceuticals (JAZZ) and Viatris (VTRS)
MetricJAZZVTRS
Volatility (1Y, Annualized)38.74%32.53%
Beta (5Y)0.330.86
Max Drawdown (5Y)-42.03%-45.69%
Avg. Volume (3M)878.80K8.87M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
JAZZ and VTRS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Jazz Pharmaceuticals (JAZZ) and Viatris (VTRS)
MetricJAZZVTRS
Sharpe Ratio (1Y)2.073.22
Sortino Ratio (1Y)4.145.63

Profitability

ROE (TTM)

Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Jazz Pharmaceuticals (JAZZ) reports 5.05%, ranking against industry peers normally.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.05%

Max
109.18%
Q3
6.23%
JAZZ
5.05%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.21%

Max
109.18%
Q3
6.23%
VTRS
-4.21%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Jazz Pharmaceuticals (JAZZ) vs. Viatris (VTRS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile Jazz Pharmaceuticals (JAZZ) reports 4.37%, ranking against industry peers normally.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.37%

Max
18.05%
Q3
4.78%
JAZZ
4.37%
Median
0.00%
Q1
-4.14%
Min
-17.05%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.13%

Max
18.05%
Q3
4.78%
Median
0.00%
VTRS
-4.13%
Q1
-4.14%
Min
-17.05%
Loading chart…
Jazz Pharmaceuticals (JAZZ) vs. Viatris (VTRS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Jazz Pharmaceuticals (JAZZ) at 30.17% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.17%

Max
83.12%
JAZZ
30.17%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.85%

Max
83.12%
Q3
14.77%
VTRS
13.85%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Jazz Pharmaceuticals (JAZZ) vs. Viatris (VTRS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Jazz Pharmaceuticals (JAZZ) and Viatris (VTRS)
MetricJAZZVTRS
ROE (TTM)5.05%-4.21%
ROA (TTM)6.92%2.91%
Net Margin (TTM)4.37%-4.13%
Operating Margin (TTM)30.17%13.85%
Gross Margin (TTM)91.10%41.13%

Growth

Revenue Growth

Jazz Pharmaceuticals (JAZZ) at 4.88% is around its peer norm for revenue growth, while Viatris (VTRS) at -2.98% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Loading chart…
Jazz Pharmaceuticals (JAZZ) vs. Viatris (VTRS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Jazz Pharmaceuticals (JAZZ) reports EPS growth of -167.51%, ranked against its industry; Viatris (VTRS) has no EPS growth figure this period.

Loading chart…
Jazz Pharmaceuticals (JAZZ) vs. Viatris (VTRS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Jazz Pharmaceuticals (JAZZ) and Viatris (VTRS)
MetricJAZZVTRS
Revenue Growth (YoY)4.88%-2.98%
Revenue Growth (3Y CAGR)5.26%-4.20%
EPS Growth (YoY)-167.51%--
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Both Jazz Pharmaceuticals (JAZZ) at 1.82 and Viatris (VTRS) at 1.55 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.82

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
JAZZ
1.82
Min
0.10

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
VTRS
1.55
Min
0.10
Loading chart…
Jazz Pharmaceuticals (JAZZ) vs. Viatris (VTRS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Jazz Pharmaceuticals (JAZZ) at 1.35 and Viatris (VTRS) at 0.99 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.35

Max
1.42
JAZZ
1.35
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.99

Max
1.42
VTRS
0.99
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Jazz Pharmaceuticals (JAZZ) vs. Viatris (VTRS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Jazz Pharmaceuticals (JAZZ) and Viatris (VTRS)
MetricJAZZVTRS
Current Ratio (MRQ)1.821.55
Debt / Equity (MRQ)1.350.99
Net Debt / EBITDA1.392.64

Dividends

Dividend Yield (TTM)

Jazz Pharmaceuticals (JAZZ) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Viatris (VTRS) reports a yield of 2.53%, ranking against industry peers normally.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

JAZZ
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.53%

VTRS
2.53%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Jazz Pharmaceuticals (JAZZ) vs. Viatris (VTRS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings; Jazz Pharmaceuticals (JAZZ) pays no dividend (payout 0.00%).

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

JAZZ
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

960.00%

VTRS
960.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Jazz Pharmaceuticals (JAZZ) vs. Viatris (VTRS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Jazz Pharmaceuticals (JAZZ) and Viatris (VTRS)
MetricJAZZVTRS
Dividend Yield (TTM)0.00%2.53%
Dividend Payout Ratio (TTM)0.00%960.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Jazz Pharmaceuticals (JAZZ) trades at 69.46 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

69.46

Max
85.34
JAZZ
69.46
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
VTRS
--
Loading chart…
Jazz Pharmaceuticals (JAZZ) vs. Viatris (VTRS): VTRS does not report P/E ratio, so it has no value marker; JAZZ is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Viatris (VTRS) at 1.55 sits in the cheaper P/S ratio quartile while Jazz Pharmaceuticals (JAZZ) at 3.19 prices around its industry’s middle — VTRS costs less per dollar of sales, though read it alongside growth and margins.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.19

Max
58.18
Q3
25.77
Median
7.30
JAZZ
3.19
Q1
3.01
Min
0.01

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
VTRS
1.55
Min
0.01
Loading chart…
Jazz Pharmaceuticals (JAZZ) vs. Viatris (VTRS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Viatris (VTRS) at 1.67 sits in the lower P/B ratio quartile against book while Jazz Pharmaceuticals (JAZZ) at 3.59 is valued near its industry’s middle — VTRS is cheaper on assets, though weigh it against ROE and asset quality.

JAZZ

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.59

Max
13.53
Q3
6.54
JAZZ
3.59
Median
3.25
Q1
1.69
Min
-5.59

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.67

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
VTRS
1.67
Min
-5.59
Loading chart…
Jazz Pharmaceuticals (JAZZ) vs. Viatris (VTRS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Jazz Pharmaceuticals (JAZZ) and Viatris (VTRS)
MetricJAZZVTRS
P/E Ratio (TTM)69.46--
P/S Ratio (TTM)3.191.55
P/B Ratio (MRQ)3.591.67
Free Cash Flow Yield (TTM)11.16%13.84%